GlaxoSmithKline submits application for COPD drug in EU
GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).
GlaxoSmithKline (GSK) has submitted a regulatory application in the EU for umeclidinium monotherapy, an investigative once-daily medicine used in patients with chrinic obstructive pulmonary disease (COPD).
The treatment, which is administered using the company's Ellipta inhaler, is designed to relive symptoms in adult suffers of COPD.
The group said a marketing authoristion application (MAA) for the treatment has been submitted to the European Medicines Agency (EMA).
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Regulatory filings for the product are imminent in the US and planned in other countries during the course of 2013, it added.
The share price was down 0.36% to 1,676p by 11:00 on Friday.
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.